SCHEMBL12174403

SCHEMBL12174403

O=C(Nc1ccc(N2CCN(CC(C(=O)NCc3ccccc3)c3ccccc3)CC2)cc1)c1ccccc1-c1ccc(C(F)(F)F)cc1

nearest known ligand 0.55

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ MTTP P55157 18/20 0.55
▸ APOB P04114 1/20 0.49
▸ NPY2R P49146 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12174534 0.91 MTTP (0.49) MTTPNPY2R
SCHEMBL2583429 0.90 MTTP (0.59) MTTPNPY2R
SCHEMBL12174450 0.89 MTTP (0.54) MTTPNPY2R
SCHEMBL12174536 0.88 MTTP (0.53) MTTPNPY2R
SCHEMBL12174382 0.87 NPY2R (0.60) MTTPAPOBNPY2R
SCHEMBL12174442 0.86 NPY2R (0.56) MTTPNPY2R
SCHEMBL12174380 0.86 MTTP (0.56) MTTPAPOBNPY2R
SCHEMBL14463105 0.84 MTTP (0.53) MTTPAPOBNPY2R
SCHEMBL2588205 0.83 HIF1A (0.64) MTTPAPOB
SCHEMBL12158118 0.81 MTTP (0.53) MTTPAPOBNPY2R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8354402-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2013-01-15 — — US disclosed
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2011-11-03 — — US disclosed
US-7528154-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICAL N.V. (BE) 2009-05-05 — — US disclosed
US-7528154-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICAL N.V. (BE) 2009-05-05 — — US disclosed
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2008-05-29 — — US disclosed
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2008-05-29 — — US disclosed
US-7253157-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-07 — — US disclosed
US-7253157-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-08-07 — — US disclosed
EP-1806341-A2 (+)Phenyl-(4-{4-[(4'-trifluoromethyl-biphenyl-2-carbonyl)-amino]-phenyl}-piperidin-1-yl)-acetic acid methyl ester as lipid lowering agent JANSSEN PHARMACEUTICA N.V. (BE) 2007-07-11 — — EP disclosed
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2007-04-12 — — US disclosed
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS MEERPOEL LIEVEN 2007-04-12 — — US disclosed
US-7169796-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-30 — — US disclosed
US-7169796-B2 Polyarylcarboxamides useful as lipid lowering agents JANSSEN PHARMACEUTICA N.V. (BE) 2007-01-30 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080125412-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB MTTP 9/4885APOB 3/4885NPY2R 4187/4885
US-20110269747-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB MTTP 9/4885APOB 3/4885NPY2R 4187/4885
US-20070082888-A1 POLYARYLCARBOXAMIDES USEFUL AS LIPID LOWERING AGENTS LIPC, PNLIP, APOB MTTP 9/4885APOB 3/4885NPY2R 4187/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback